Physician profile
Bliss Jensen
NPI 1588154470
$11,235.36
in general payments reported to CMS, 2019-2025
47 companies · $2,826 in 2025
The $2,826 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,946 · 2022: $1,782 · 2023: $1,872 · 2024: $2,809 · 2025: $2,826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,506.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,736.98 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,558.52 | 2021-2025 | |
| Amgen INC. | $1,231.31 | 2021-2025 | Repatha, Evenity, Otezla |
| Novo Nordisk INC | $1,040.22 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $837.37 | 2021-2025 | |
| Lilly USA, LLC | $819.89 | 2021-2025 | Zepbound, Jardiance, Mounjaro |
| Biohaven Pharmaceuticals, INC. | $330.71 | 2021 | |
| Daiichi Sankyo INC. | $295.32 | 2021-2025 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $279.09 | 2025 | Xifaxan |
| Glaxosmithkline, LLC. | $250.83 | 2021-2025 | Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $234.77 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.46 | 2021-2024 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $202.75 | 2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $198.21 | 2022 | |
| Phathom Pharmaceuticals, INC. | $155.46 | 2024-2025 | Voquezna |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bliss Jensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.